代谢功能障碍相关脂肪性肝病所致代偿期进展性慢性肝病患者首次及进一步失代偿的影响
这项国际多中心回顾性研究纳入6061例代谢功能障碍相关脂肪性肝病所致代偿期进展性慢性肝病患者,评估首次及进一步失代偿的累积发生率及其对肝相关死亡的影响。5年首次失代偿累积发生率为3.5%,与肝相关死亡病因特异性风险增加18.9倍相关;发生首次失代偿后5年进一步失代偿累积发生率为43.9%,使肝相关死亡风险进一步增加1.52倍。肝细胞癌是肝相关死亡的独立预测因素。
要点
- 5年首次失代偿累积发生率为3.5%,与肝相关死亡风险增加18.9倍相关。
- 首次失代偿后5年进一步失代偿累积发生率为43.9%,肝相关死亡风险进一步增加1.52倍。
- 腹水是最常见的失代偿事件,肝细胞癌独立增加肝相关死亡风险。
核心结论
- 首次及后续失代偿事件是代谢功能障碍相关脂肪性肝病所致代偿期进展性慢性肝病临床进展的主要转折点,分别使肝相关死亡病因特异性风险增加18.9倍和额外增加1.52倍。
- 肝细胞癌是肝相关死亡的独立预测因素,与失代偿并存时进一步加剧死亡风险。
研究设计与样本
- 国际多中心(17个中心)回顾性研究,纳入6061例连续患者,代偿期进展性慢性肝病由代谢功能障碍相关脂肪性肝病所致,经临床(肝脏硬度测量>10 kPa)或组织学(F3-F4纤维化)诊断。
- 失代偿事件依据Baveno VII标准定义,采用累积发生率函数和病因特异性Cox模型(含基线和时依变量)分析竞争风险,并构建多状态模型描述临床轨迹。
主要发现
- 5年首次失代偿累积发生率为3.5%(95% CI 3.0-4.1),与肝相关死亡病因特异性风险增加18.9倍(95% CI 10.8-32.9)相关。
- 发生首次失代偿的患者中,5年进一步失代偿累积发生率为43.9%(95% CI 37.2-50.2),使肝相关死亡风险进一步增加1.52倍(95% CI 1.02-2.34)。
- 腹水是最常见的失代偿事件,其次为食管胃静脉曲张出血。
- 肝细胞癌使总体队列肝相关死亡病因特异性风险独立增加2.95倍(95% CI 2.02-4.31),在发生过首次失代偿的患者中增加1.43倍(95% CI 1.03-2.00)。
- 急性和非急性失代偿对肝相关死亡的贡献相似,肝外死亡也构成相当负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: First and further decompensation events mark key transitions in the natural history of cirrhosis and significantly influence mortality risk. We assessed the cumulative incidence of first and further (acute and non-acute) decompensation and evaluated their impact on liver-related death (LR-D) in patients with compensated advanced chronic liver disease (cACLD) due to metabolic dysfunction-associated steatotic liver disease (MASLD). METHODS: We conducted an international, multicenter (17 centers), retrospective study involving 6,061 consecutive patients with cACLD due to MASLD, diagnosed either clinically (liver stiffness measurement >10 kPa) or histologically (F3-F4 fibrosis). Decompensation events were defined according to the Baveno VII criteria. Cumulative incidence functions and cause-specific Cox models (with baseline and time-dependent variables) were used to analyze competing risks. A multistate model was developed to better describe the clinical trajectory of cACLD due to MASLD. RESULTS: The 5-year cumulative incidence of first decompensation was 3.5% (95% CI 3.0-4.1), which was associated with an 18.9-fold increase (95% CI 10.8-32.9) in the cause-specific hazard of LR-D. Among patients who experienced a first decompensation, the 5-year cumulative incidence of further decompensation was 43.9% (95% CI 37.2-50.2), further increasing the hazard of LR-D by 1.52-fold (95% CI 1.02-2.34). Ascites, followed by variceal bleeding, were the most common decompensation events. Hepatocellular carcinoma independently increased the cause-specific hazard of LR-D by 2.95-fold (95% CI 2.02-4.31) in the overall cohort and by 1.43-fold (95% CI 1.03-2.00) in patients who had experienced a first decompensation. CONCLUSIONS: First and subsequent decompensation events are major inflection points in the clinical progression of cACLD due to MASLD, increasing the cause-specific hazard of LR-D by 18.9- and an additional 1.52-fold, respectively. Hepatocellular carcinoma is an independent predictor of LR-D and further exacerbates mortality risk when present alongside decompensation. IMPACT AND IMPLICATIONS: In this large international multicenter cohort of 6,061 patients with compensated advanced chronic liver disease (cACLD) due to metabolic dysfunction-associated steatotic liver disease (MASLD), we examined the clinical impact of first and further decompensation events. At 5 years, the cumulative incidences of first and further decompensation were 3.5% and 43.9%, respectively, each significantly increasing the cause-specific hazard of liver-related death (18.9-fold and 1.52-fold). Ascites, more so than variceal bleeding, was the predominant and most impactful event. Both acute and non-acute decompensation similarly contributed to liver-related mortality. Additionally, hepatocellular carcinoma independently increased the hazard of liver-related death, even post-decompensation. Notably, extrahepatic deaths also represented a considerable burden, reflecting the high metabolic risk of MASLD. These findings highlight key prognostic inflection points in MASLD-related cACLD.
引用
- Pennisi G, Di Maria G, Wong VW, et al. Impact of first and further decompensation in patients with compensated ACLD due to MASLD. J Hepatol. 2025. PMID: 40550340. doi:10.1016/j.jhep.2025.06.014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。